- Home
- WYY vs IGC Comparison
WYY vs IGC Comparison
Compare WYY & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- IGC
- Stock Information
- Founded
- WYY 1991
- IGC 2005
- Country
- WYY United States
- IGC United States
- Employees
- WYY N/A
- IGC N/A
- Industry
- WYY EDP Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- WYY Technology
- IGC Health Care
- Exchange
- WYY Nasdaq
- IGC Nasdaq
- Market Cap
- WYY 32.7M
- IGC 26.9M
- IPO Year
- WYY 1998
- IGC N/A
- Fundamental
- Price
- WYY $4.81
- IGC $0.35
- Analyst Decision
- WYY Strong Buy
- IGC Strong Buy
- Analyst Count
- WYY 1
- IGC 2
- Target Price
- WYY $7.00
- IGC $3.63
- AVG Volume (30 Days)
- WYY 77.0K
- IGC 222.5K
- Earning Date
- WYY 11-13-2024
- IGC 11-12-2024
- Dividend Yield
- WYY N/A
- IGC N/A
- EPS Growth
- WYY N/A
- IGC N/A
- EPS
- WYY N/A
- IGC N/A
- Revenue
- WYY $133,124,648.00
- IGC $1,183,000.00
- Revenue This Year
- WYY $25.94
- IGC N/A
- Revenue Next Year
- WYY $13.22
- IGC $13.57
- P/E Ratio
- WYY N/A
- IGC N/A
- Revenue Growth
- WYY 31.67
- IGC N/A
- 52 Week Low
- WYY $1.65
- IGC $0.25
- 52 Week High
- WYY $5.31
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- WYY 67.67
- IGC 42.76
- Support Level
- WYY $4.25
- IGC $0.33
- Resistance Level
- WYY $5.31
- IGC $0.42
- Average True Range (ATR)
- WYY 0.33
- IGC 0.02
- MACD
- WYY 0.11
- IGC -0.00
- Stochastic Oscillator
- WYY 70.98
- IGC 32.14
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically the company generates a majority of its revenue from the United States and rest from Europe.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.